Diabetes Pro Quarterly - Summer 2020 - 22

Mission News

Content-Rich Diabetes Care Issue Features COVID-19
Collection, Cost Analyses of Diabetes Interventions,
and New Consensus Reports
The July 2020 issue of Diabetes Care includes a collection
of research on COVID-19 and diabetes, two reviews of the
costs of diabetes interventions, and new consensus reports on
precision medicine and diabetes self-management education
and support (DSMES).

"Because diabetes is one of the conditions associated with high
risk, the diabetes community urgently needs to know more
about COVID-19 and its effects on people with diabetes," write
Diabetes Care Editor-in-Chief Matthew C. Riddle and colleagues
in a commentary introducing the COVID-19 collection (https://
care.diabetesjournals.org/content/43/7/1378). To address
that need, the collection includes:
* Explorations of the characteristics, risk factors, and outcomes of
people with diabetes and COVID-19
* Articles on links between obesity and increased COVID-19
severity

* Investigations to determine whether type of glucose-lowering
therapy or degree of glycemic control affect COVID-19
outcomes

* A description of the use of continuous glucose monitoring for
remote surveillance in intensive care units
* A look at possible associations between increased expression
of the possible coronavirus receptor angiotensin-converting
enzyme 2 and COVID-19 outcomes in people with diabetes
* Expert assessments of important research and treatment
challenges and opportunities posed by COVID-19

"The frequency of diabetes among patients requiring intensive
care is two to three times higher than in the overall population,

and mortality rates in those with diabetes are also higher," Riddle
et al. write. "Neither the mechanisms underlying the increased
risk nor the best interventions to limit it have yet been defined,
but [these studies] offer important clues."
Cost Effectiveness of Diabetes Interventions
The July issue also includes two American Diabetes Association
(ADA)/Centers for Disease Control and Prevention systematic
reviews of the economic value of diabetes-related interventions.
The first explores the costs of lifestyle intervention or metformin
therapy for people at high risk of developing type 2 diabetes
[https://doi.org/10.2337/dci20-0018]. The second reviews
studies evaluating the cost-effectiveness of ADA-recommended
diabetes management interventions [https://doi.org/10.2337/
dci20-0017]. The reviews are intended to inform the wise
allocation of limited health care dollars.
Precision Medicine in Diabetes
An expert consensus report on precision medicine in diabetes
care [https://doi.org/10.2337/dci20-0022] is also featured in
the issue. The report introduces the ADA/European Association
for the Study of Diabetes Precision Medicine in Diabetes
Initiative, reviews the current state of the field and its prospects
for the future, and enumerates key barriers to and opportunities
for implementing precision diabetes medicine.
Diabetes Self-Management Education and Support
Diabetes self-management education and support (DSMES) is
the topic of a second consensus report in the journal's July issue
[https://doi.org/10.2337/dci20-0023]. This report is described
in more details in a separate article on p. 23.

"Living Standards of Care" Update Released
The American Diabetes Association (ADA) in June issued
important online updates to its Standards of Medical Care in
Diabetes-2020. These revisions, part of a periodic updating
process known as the "Living Standards of Care in Diabetes,"
included changes to the risk management and treatment of
cardiovascular disease, revisions to safety labels for sodium-
glucose cotransporter 2 (SGLT2) inhibitors, new data on
closed-loop glycemic management in type 1 diabetes, and
inclusion of the U.S. Food and Drug Administration (FDA)
withdrawal of the weight loss medication lorcaserin. Recently
published research and information from the FDA prompted
these amendments to the 2020 Standards of Care.
22

DiabetesPro Quarterly | SUMMER 2020

The latest Living Standards updates include the following
changes.
* Section 10, "Cardiovascular Disease and Risk Management,"
now incorporates evidence from the CAROLINA
(Cardiovascular Outcome Study of Linagliptin Versus
Glimepiride in Patients With Type 2 Diabetes) trial. The
study demonstrated noninferiority between the dipeptidyl
peptidase 4 inhibitor linagliptin and the sulfonylurea
glimepiride on cardiovascular outcomes, despite lower
rates of hypoglycemia in the linagliptin treatment group.
The DAPA-HF (Dapagliflozin in Patients with Heart Failure
continued on next page
https://care.diabetesjournals.org/content/43/7/1378 https://care.diabetesjournals.org/content/43/7/1378 https://www.doi.org/10.2337/dci20-0018 https://www.doi.org/10.2337/dci20-0017 https://www.doi.org/10.2337/dci20-0017 https://www.doi.org/10.2337/dci20-0022 https://www.doi.org/10.2337/dci20-0023
Diabetes Pro Quarterly - Summer 2020

Table of Contents for the Digital Edition of Diabetes Pro Quarterly - Summer 2020
